Roflumilast: A Review in COPD

Drugs

Volumn 75, Issue 14, 2015, Pages 1645-1656

  Garnock Jones, Karly P ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ROFLUMILAST; AMINOPYRIDINE DERIVATIVE; BENZAMIDE DERIVATIVE; CYCLOPROPANE DERIVATIVE;

CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY ASSESSMENT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; EMPHYSEMA; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INHIBITORY CONCENTRATION; LUNG FUNCTION; MAXIMUM PLASMA CONCENTRATION; OUTCOME ASSESSMENT; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VOLUME OF DISTRIBUTION; WEIGHT REDUCTION; DRUG TOLERANCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

AMINOPYRIDINES; BENZAMIDES; CYCLOPROPANES; DRUG TOLERANCE; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84942504004     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0463-1     Document Type: Review

References (58)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategies for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2015. http://www.goldcopd.org. Accessed 25 May 2015.
2. ® (roflumilast tablets): EU summary of product characteristics. 2011. http://www.ema.europa.eu. Accessed 29 Jul 2015.
3. Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol. 2011;163(1):53-67.
4. Giembycz MA, Maurice DH. Cyclic nucleotide-based therapeutics for chronic obstructive pulmonary disease. Curr Opin Pharmacol. 2014;16(Suppl C):89-107.
5. ® (roflumilast tablets): US prescribing information. 2014. http://pi.actavis.com. Accessed 29 Jul 2015.
6. Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther. 2001;297(1):267-79.
7. Buenestado A, Grassin-Delyle S, Guitard F, et al. Roflumilast inhibits the release of chemokines and TNF-alpha from human lung macrophages stimulated with lipopolysaccharide. Br J Pharmacol. 2012;165(6):1877-90.
8. Buenestado A, Chaumais MC, Grassin-Delyle S, et al. Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-alpha and chemokine production by human lung parenchyma. PLoS One. 2013;8(9):e74640.
9. Victoni T, Gleonnec F, Lanzetti M, et al. Roflumilast N-oxide prevents cytokine secretion induced by cigarette smoke combined with LPS through JAK/STAT and ERK1/2 inhibition in airway epithelial cells. PLoS One. 2014;9(1):e85243.
10. Vecchio D, Acquaviva A, Arezzini B, et al. Downregulation of NOX4 expression by roflumilast N-oxide reduces markers of fibrosis in lung fibroblasts. Mediators Inflamm. 2013;2013:745984.
11. Höhne K, Schließmann SJ, Kirschbaum A, et al. Roflumilast-N-oxide induces surfactant protein expression in human alveolar epithelial cells type II. PLoS One. 2012;7(7):e38369.
12. Milara J, Armengot M, Banuls P, et al. Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro. Br J Pharmacol. 2012;166(8):2243-62.
13. Milara J, Peiro T, Serrano A, et al. Roflumilast N-oxide inhibits bronchial epithelial to mesenchymal transition induced by cigarette smoke in smokers with COPD. Pulm Pharmacol Ther. 2014;28(2):138-48.
14. Milara J, Lluch J, Almudever P, et al. Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2014;134(2):314-22.
15. Milara J, Morell A, Ballester B, et al. Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist. Respir Res. 2015;16:12.
16. Hatzelmann A, Morcillo EJ, Lungarella G, et al. The preclinical pharmacology of roflumilast: a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2010;23(4):235-56.
17. Martorana PA, Beume R, Lucattelli M, et al. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med. 2005;172(7):848-53.
18. Hohlfeld JM, Schoenfeld K, Lavae-Mokhtari M, et al. Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial. Pulm Pharmacol Ther. 2008;21(4):616-23.
19. Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax. 2007;62(12):1081-7.
20. Marquez-Martin E, Ortega F, Campano E, et al. Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD [abstract no. 732A]. Chest. 2013;144(4 MeetingAbstracts). doi: 10.1378/chest.1703911.
21. Huennemeyer A, Nassr N, Bredenbröker D, et al. Supra-therapeutic doses of roflumilast have no effect on cardiac repolarization in healthy subjects. Expert Opin Drug Saf. 2011;10(4):509-19.
22. Bethke TD, Lahu G. High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast. Int J Clin Pharmacol Ther. 2011;49(1):51-7.
23. Hauns B, Hermann R, Hunnemeyer A, et al. Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects. J Clin Pharmacol. 2006;46(10):1146-53.
24. Bethke TD, Huennemeyer A, Lahu G, et al. Chronopharmacology of roflumilast: a comparative pharmacokinetic study of morning versus evening administration in healthy adults. Chronobiol Int. 2010;27(9-10):1843-53.
25. de Mey C, Nassr N, Lahu G. No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study. BMC Clin Pharmacol. 2011;11:7.
26. McCracken N, Lahu G, Bethke TD. Lack of pharmacokinetic and pharmacodynamic interactions of roflumilast with (R, S)-warfarin in healthy adult subjects. Int J Clin Pharmacol Ther. 2011;49(6):388-96.
27. Lee SD, Hui DS, Mahayiddin AA, et al. Roflumilast in Asian patients with COPD: a randomized placebo-controlled trial. Respirology. 2011;16(8):1249-57.
28. O'Donnell DE, Bredenbroker D, Brose M, et al. Physiological effects of roflumilast at rest and during exercise in COPD. Eur Respir J. 2012;39(5):1104-12.
29. Zheng J, Yang J, Zhou X, et al. Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group study. Chest. 2014;145(1):44-52.
30. Rabe KF, Bateman ED, O'Donnell D, et al. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2005;366(9485):563-71.
31. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374(9691):685-94.
32. Calverley PM, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176(2):154-61.
33. National Institute for Health and Clinical Excellence. Premeeting briefing: roflumilast for the management of chronic obstructiv pulmonary disease. 2011. http://www.nice.org.uk. Accessed 29 Jul 2015.
34. Takeda. OPUS study: effect of roflumilast on exacerbation rate in patients with chronic obstructive pulmonary disease (BY217/M2-111) [NCT00076089]. 2012. http://www.clinicaltrials.gov. Accessed 29 Jul 2015.
35. Creanga D, Bredenbroeker D, Brose M, et al. Effect of roflumilast treatment on dyspnea in patients with chronic obstructive pulmonary disease [abstract no. 97670]. J Hosp Med. 2012;7(Suppl 2):127.
36. Creanga D, Bredenbroeker D, Brose M, et al. Effect of roflumilast treatment on health-related quality of life in patients with chronic obstructive pulmonary disease [abstract no. 97664]. J Hosp Med. 2012;7(Suppl 2):121.
37. Rennard SI, Calverley PM, Goehring UM, et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast: the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:18.
38. Hanania NA, Calverley PM, Dransfield MT, et al. Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD. Respir Med. 2014;108(2):366-75.
39. Bateman ED, Rabe KF, Calverley PM, et al. Roflumilast with long-acting beta2-agonists for COPD: influence of exacerbation history. Eur Respir J. 2011;38(3):553-60.
40. Wedzicha JA, Rabe KF, Martinez FJ, et al. Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest. 2013;143(5):1302-11.
41. Rennard SI, Sun SX, Tourkodimitris S, et al. Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials. Int J Chron Obstruct Pulmon Dis. 2014;9:657-73.
42. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009;374(9691):695-703.
43. Martinez FJ, Calverley PMA, Goehring U-M, et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385(9971):857-66.
44. Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;11:Cd002309.
45. Oba Y, Lone NA. Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Respir Dis. 2013;7(1):13-24.
46. Yan JH, Gu WJ, Pan L. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis. Pulm Pharmacol Ther. 2014;27(1):83-9.
47. Pan L, Guo YZ, Zhang B, et al. Does roflumilast improve dyspnea in patients with chronic obstructive pulmonary disease? A meta-analysis. J Thorac Dis. 2013;5(4):422-9.
48. Wouters EFM, Teichmann P, Brose M, et al. Effects of roflumilast, a phosphodiesterase 4 inhibitor, on body composition in chronic obstructive pulmonary disease [abstract]. Am J Respir Crit Care Med. 2010;181:A4473.
49. Calverley PMA, Fabbri LM, Rabe KF, et al. Roflumilast in the treatment of COPD: a pooled safety analysis [abstract no. P4001]. In: The European Respiratory Society Annual Congress; 2010.
50. White WB, Cooke GE, Kowey PR, et al. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest. 2013;144(3):758-65.
51. Ferguson G, Hanania N, Goehring UM, et al. Respiratory-associated adverse events in the roflumilast COPD safety pool [abstract]. Chest. 2012;142(4 Suppl 1):665A.
52. Solem CT, Sun SX, Sudharshan L, et al. Exacerbation-related impairment of quality of life and work productivity in severe and very severe chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2013;8:641-52.
53. White WB, Kowey PR, Zhu H. Evaluation of major adverse cardiac events (MACE) in a one-year, placebo-controlled study of roflumilast in patients with chronic obstructive pulmonary disease (COPD): rationale and design [abstract no. F68]. Am J Respir Crit Care Med. 2013;187:A1484.
54. Yu T, Fain K, Boyd CM, et al. Benefits and harms of roflumilast in moderate to severe COPD. Thorax. 2014;69(7):616-22.
55. Samyshkin Y, Kotchie RW, Mork AC, et al. Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. Eur J Health Econ. 2014;15(1):69-82.
56. Hertel N, Kotchie RW, Samyshkin Y, et al. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. Int J Chron Obstruct Pulmon Dis. 2012;7:183-99.
57. Nowak D, Ehlken B, Kotchie R, et al. Roflumilast in combination with long-acting bronchodilators in the management of patients with severe and very severe COPD. A cost-effectiveness analysis for Germany. Dtsch Med Wochenschr. 2013;138(4):119-25.
58. Samyshkin Y, Schlunegger M, Haefliger S, et al. Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland. Int J Chron Obstruct Pulmon Dis. 2013;8:79-87.